These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 26501898)

  • 1. HTRF Kinase Assay Development and Methods in Inhibitor Characterization.
    Jia Y; Manuia M; Juarez J
    Methods Mol Biol; 2016; 1360():1-18. PubMed ID: 26501898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitory activity of dehydroabietylamine derivatives tested by homogeneous time-resolved fluorescence based high throughput screening model.
    Zhou TT; He L; Yan M; Zhang LY; He JG; Rao XP
    Chin J Nat Med; 2013 Sep; 11(5):506-13. PubMed ID: 24359775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence.
    Park YW; Cummings RT; Wu L; Zheng S; Cameron PM; Woods A; Zaller DM; Marcy AI; Hermes JD
    Anal Biochem; 1999 Apr; 269(1):94-104. PubMed ID: 10094779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the utility of the HTRF Transcreener ADP assay technology: a comparison with the standard HTRF assay technology.
    Hong L; Quinn CM; Jia Y
    Anal Biochem; 2009 Aug; 391(1):31-8. PubMed ID: 19406097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for small molecule inhibitors of insulin-like growth factor receptor (IGF-1R) kinase: comparison of homogeneous time-resolved fluorescence and 33P-ATP plate assay formats.
    Wang Y; Malkowski M; Hailey J; Turek-Etienne T; Tripodi T; Pachter JA
    J Exp Ther Oncol; 2004 Jul; 4(2):111-9. PubMed ID: 15500006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of HTRF(®) technology in kinase assays.
    Jia Y
    Expert Opin Drug Discov; 2008 Dec; 3(12):1461-74. PubMed ID: 23506109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
    Zalcman G
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S5-6. PubMed ID: 17242635
    [No Abstract]   [Full Text] [Related]  

  • 8. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
    Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
    Carey KD; Garton AJ; Romero MS; Kahler J; Thomson S; Ross S; Park F; Haley JD; Gibson N; Sliwkowski MX
    Cancer Res; 2006 Aug; 66(16):8163-71. PubMed ID: 16912195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of various in vitro COT kinase assay formats and their applications in inhibitor identification and characterization.
    Jia Y; Quinn CM; Clabbers A; Talanian R; Xu Y; Wishart N; Allen H
    Anal Biochem; 2006 Mar; 350(2):268-76. PubMed ID: 16356459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TR-FRET binding assay targeting unactivated form of Bruton's tyrosine kinase.
    Asami T; Kawahata W; Sawa M
    Bioorg Med Chem Lett; 2015; 25(10):2033-6. PubMed ID: 25872980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplexing terbium- and europium-based TR-FRET readouts to increase kinase assay capacity.
    Horton RA; Vogel KW
    J Biomol Screen; 2010 Sep; 15(8):1008-15. PubMed ID: 20460248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity-based kinase profiling of approved tyrosine kinase inhibitors.
    Kitagawa D; Yokota K; Gouda M; Narumi Y; Ohmoto H; Nishiwaki E; Akita K; Kirii Y
    Genes Cells; 2013 Feb; 18(2):110-22. PubMed ID: 23279183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a time-resolved fluorescence resonance energy transfer assay for cyclin-dependent kinase 4 and identification of its ATP-noncompetitive inhibitors.
    Lo MC; Ngo R; Dai K; Li C; Liang L; Lee J; Emkey R; Eksterowicz J; Ventura M; Young SW; Xiao SH
    Anal Biochem; 2012 Feb; 421(2):368-77. PubMed ID: 22056947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
    Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
    Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications.
    Degorce F; Card A; Soh S; Trinquet E; Knapik GP; Xie B
    Curr Chem Genomics; 2009 May; 3():22-32. PubMed ID: 20161833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.
    Suzuki T; Fujii A; Ohya J; Amano Y; Kitano Y; Abe D; Nakamura H
    Cancer Sci; 2007 Dec; 98(12):1977-84. PubMed ID: 17888033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.